Andrographolide significantly reduces the phosphorylation of p38 MAPK and ERK1/2, as well as IL-1β and IL-6 content in TNF-α-stimulated fibroblast-like synovial cells, which may treat RA by inhibiting the MAPK pathway (Li et al., 2017). The gene discussed is IL6; the disease is rheumatoid arthritis.